Neurobrave

NeuroBrave operates at the intersection of neurotechnology, digital health, wearable computing, and software analytics. Its stated proposition differs from device-first neurotechnology companies by emphasizing a hardware-agnostic software layer that can accept data from smartwatches, EEG, ECG, EMG, earphones, controllers, and AR/VR devices. The company’s NeuroSpeed OS platform combines sensor fusion, signal processing, deep-learning models, cloud delivery, dashboards, and a streaming API. That architecture gives it a potential integration advantage for businesses that already control or distribute wearable hardware, although the available profile does not establish customer counts, recurring revenue, regulatory clearances, or product adoption. The company also differs from general wellness-app providers through its focus on neuromarkers, cognitive states, and physiological interpretation rather than only activity or symptom tracking. Its 2024 work with Sourasky Medical Center suggests credibility in clinical or research-oriented environments, while the gaming and manufacturing use cases broaden the addressable market.

NeuroBrave was founded in July 2020 and raised $1.9 million in a pre-seed round dated Apr 1, 2021, followed by non-equity assistance on Apr 13, 2021, a seed round on May 1, 2022, and a $300,000 angel round on Aug 19, 2022. The four recorded rounds total $2.2 million, providing early financing for development of its biosignal-processing platform. The product scope has expanded from a general wearable-based cognitive-state proposition to a defined software stack: NeuroSpeed OS, Sensor Fusion, Neuro Insights, a signal-processing engine, neuromarker generation, and cloud APIs. A notable inflection point came in 2023, when the company’s AI, signal-processing, and neuroscience approach received broader technology coverage. In April 2024, its partnership with Sourasky Medical Center indicated an institutional and generative-AI direction; July 2024 coverage then highlighted smartwatch-based mental-health monitoring. The company is listed as active with an estimated 11–50 employees, but no hiring trend, revenue data, later financing, or product-release cadence is disclosed. As a result, the trajectory shows technical and partnership development through 2024, but limited evidence of scale after the last financing in 2022.